PressSeptember 26, 2023 Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020
PressSeptember 26, 2023 Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
BlogSeptember 22, 2023 Psychedelic Education is Adapting to Meet the Needs of the Modern Psychedelic Industry
PressSeptember 21, 2023 Transcend Therapeutics and Yale awarded U.S. Department of Defense grant to study methylone for PTSD
PressSeptember 21, 2023 Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
PressSeptember 21, 2023 Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
PressSeptember 21, 2023 Filament Health and Jaguar Health Joint Venture Magdalena Biosciences Completes Import of Coca Leaf From Peru
BlogSeptember 20, 2023 Lucy Scientific Discovery: Navigating Growth and Diversification in the Psychedelic and Wellness Sectors
PressSeptember 20, 2023 Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
PressSeptember 19, 2023 The Healing Company to Present at the LD Micro Main Event XVI Investor Conference on October 4th
PressSeptember 19, 2023 Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
PressSeptember 19, 2023 Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
PressSeptember 18, 2023 FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated
PressSeptember 18, 2023 Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
